Javier Terriente

Javier Terriente is a prominent figure in the Spanish biotechnology sector, currently serving as a Board Member at AseBio (Asociación Española de Empresas Biotecnológicas), the Spanish association of biotech companies.13

Professional Background

Dr. Javier Terriente is a biochemist with a Ph.D. in developmental genetics.1 He has over 20 years of research experience in both academic and biotech sectors.1 His career highlights include:

• Co-founder of ZeClinics in 20131
• Co-founder of ZeCardio Therapeutics, a spinout from ZeClinics focused on discovering therapies for cardiovascular diseases1
• Chief Scientific Officer (CSO) at ZeClinics from 2013 to 20201
• Currently serves as Chief of Drug Discovery at ZeClinics and CSO at ZeCardioTx1

Expertise and Contributions

Javier Terriente is known for his expertise in:

• Zebrafish biology and its application in drug discovery
• Managing scientific teams and directing Ph.D. theses
• Publishing research articles on using zebrafish for drug and target discovery1

Role at AseBio

As a Board Member at AseBio, Javier Terriente contributes to the organization's mission of promoting and developing Spanish biotechnology companies.2 He is also involved in the Healthcare Committee of AseBio, which focuses on:

• Influencing regulatory processes affecting biotechnology in healthcare
• Improving access to biotechnological innovations in the Spanish Healthcare System
• Raising awareness about biotechnology's contributions to healthcare3

Javier Terriente's election to the AseBio Board of Directors was announced in December 2023, reflecting his significant standing in the Spanish biotech community.45